PHAT

Insider Trades

Name	Value	Action	Price	Current Price
Breedlove Robert CharlesPrincipal Accounting Officer $7.1k524 shares SellNov 3, 2025 $13.51 --
Breedlove Robert CharlesPrincipal Accounting Officer $5.6k461 shares SellSep 5, 2025 $12.09 --
Breedlove Robert CharlesPrincipal Accounting Officer $14k1.7k shares SellJul 16, 2025 $8.36 --
Topper James NDirector $15k3.8k shares BuyMay 21, 2025 $3.86 --
Topper James NDirector $21k6.3k shares BuyMay 14, 2025 $3.32 --
Topper James NDirector $3.5k1.1k shares BuyMay 13, 2025 $3.16 --

Trade PHAT

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

CEO: Steven L. Basta
IPO Date: Oct 25, 2019

Market Data

Open: $11.24
High: $11.34
Low: $10.59
Volume: 1.1M
Avg Volume: 1.2M
52W High: $18.31
52W Low: $7.61

Valuation

Market Cap: $868M
Enterprise Value: $853M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-167M
Revenue: $175M
Net Income: $-221M
Cash: $130M
Debt: $212M

Events

EarningsAug 6

EPS est. -0.20713